Details of the Drug

General Information of Drug (ID: DM2HG4X)

Drug Name

Prednisone

Synonyms

Adasone; Ancortone; Bicortone; Cartancyl; Colisone; Cortan; Cortidelt; Cotone; Dacorten; Dacortin; Decortancyl; Decortin; Decortisyl; Dehydrocortisone; Dekortin; Dellacort; Deltacortene; Deltacortisone; Deltacortone; Deltasone; Deltison; Deltisona; Deltisone; Deltra; Diadreson; Econosone; Encorton; Encortone; Enkortolon; Enkorton; Fiasone; Hostacortin; Incocortyl; Juvason; Kortancyl; Lisacort; Lodotra; Metacortandracin; Meticorten; Nisona; Nizon; Novoprednisone; Nurison; Orasone; Panafcort; Panasol; Paracort; Parmenison; Pehacort; Precort; Predeltin; Prednicorm; Prednicort; Prednicot; Prednidib; Prednilonga; Prednison; Prednisona; Prednisonum; Prednitone; Prednizon; Prednovister; Presone; Pronison; Pronisone; Rectodelt; Retrocortine; Servisone; Sone; Sterapred; Supercortil; Ultracorten; Ultracortene; Winpred; Wojtab; Zenadrid; Dellacort A; Delta E; Delta cortelan; Liquid Pred; Origen Prednisone; Prednisone Intensol; Zenadrid [veterinary]; P1276; U 6020; Apo-Prednisone; Delta E.; Delta-Cortelan; Delta-Cortisone; Delta-Cortone; Delta-Dome; Delta-E; Delta1-Cortisone; Delta1-Dehydrocortisone; Di-Adreson; In-Sone; Me-Korti; Meticortelone (TN); Meticorten (TN); Meticorten (Veterinary); Metrevet (Veterinary); Prednicen-M; Prednisona [INN-Spanish]; Prednisone [INN:BAN]; Prednisonum [INN-Latin]; SK-Prednisone; Zenadrid (veterinary); Delta(sup 1)-Cortisone; Delta(sup 1)-Dehydrocortisone; Delta(sup1)-Cortisone; Delta-1-Cortisone; Delta-1-Dehydrocortisone; Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone; (1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione; (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione; (8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione; 1,2-Dehydrocortisone; 1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione; 1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione; 1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione; 1-Cortisone; 1-Dehydrocortisone; 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione; 17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione

Indication

Disease Entry	ICD 11	Status	REF
Inflammation	1A00-CA43.1	Approved	[1], [2]
Atopic dermatitis	EA80	Phase 1	[3]
Eczema	EA80-EA89	Phase 1	[3]

Therapeutic Class

Antiinflammatory Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

358.4

Topological Polar Surface Area (xlogp)

1.5

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Bioavailability: 70% of drug becomes completely available to its intended biological destination(s) [5]
Clearance: The drug present in the plasma can be removed from the body at the rate of 2.5 mL/min/kg [6]
Elimination: 3% of drug is excreted from urine in the unchanged form [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 2.9 hours [6]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 7.971 micromolar/kg/day [7]
Unbound Fraction: The unbound fraction of drug in plasma is 0.27% [6]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.57 L/kg [6]
Water Solubility: The ability of drug to dissolve in water is measured as 0.133 mg/mL [4]

Chemical Identifiers

Formula: C21H26O5
IUPAC Name: (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
Canonical SMILES: C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C
InChI: InChI=1S/C21H26O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-15,18,22,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1
InChIKey: XOFYZVNMUHMLCC-ZPOLXVRWSA-N

Cross-matching ID

PubChem CID: 5865
ChEBI ID: CHEBI:8382
CAS Number: 53-03-2
DrugBank ID: DB00635
TTD ID: D0IL7L
VARIDT ID: DR00438
INTEDE ID: DR1334
ACDINA ID: D00552

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glucocorticoid receptor (NR3C1)	TTYRL6O	GCR_HUMAN	Agonist	[8]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[10]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Inflammation

ICD Disease Classification

1A00-CA43.1

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Glucocorticoid receptor (NR3C1)	DTT	NR3C1	7.57E-01	-0.04	-0.07
P-glycoprotein 1 (ABCB1)	DTP	P-GP	7.83E-01	4.69E-02	1.89E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	6.06E-01	-2.42E-02	-1.64E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Prednisone

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Choline salicylate	DM8P137	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Prednisone and Choline salicylate.	Postoperative inflammation [1A00-CA43]	[33]
Bromfenac	DMKB79O	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Prednisone and Bromfenac.	Postoperative inflammation [1A00-CA43]	[34]
-----------

Coadministration of a Drug Treating the Disease Different from Prednisone (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sodium bicarbonate	DMMU6BJ	Minor	Decreased absorption of Prednisone due to altered gastric pH caused by Sodium bicarbonate.	Acidosis [5C73]	[35]
Methylphenobarbital	DMDSWAG	Moderate	Increased metabolism of Prednisone caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[36]
Posaconazole	DMUL5EW	Moderate	Decreased metabolism of Prednisone caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[37]
Levalbuterol	DM5YBO1	Minor	Increased risk of hypokalemia by the combination of Prednisone and Levalbuterol.	Asthma [CA23]	[38]
Terbutaline	DMD4381	Minor	Increased risk of hypokalemia by the combination of Prednisone and Terbutaline.	Asthma [CA23]	[37]
Pirbuterol	DMI5678	Minor	Increased risk of hypokalemia by the combination of Prednisone and Pirbuterol.	Asthma [CA23]	[37]
Salbutamol	DMN9CWF	Minor	Increased risk of hypokalemia by the combination of Prednisone and Salbutamol.	Asthma [CA23]	[38]
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Prednisone and Roflumilast.	Asthma [CA23]	[39]
Formoterol	DMSOURV	Minor	Increased risk of hypokalemia by the combination of Prednisone and Formoterol.	Asthma [CA23]	[37]
Ofloxacin	DM0VQN3	Major	Increased risk of tendinitis/tendon rupture by the combination of Prednisone and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[40]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Prednisone caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[41]
Clarithromycin	DM4M1SG	Moderate	Decreased metabolism of Prednisone caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[37]
Trovafloxacin	DM6AN32	Major	Increased risk of tendinitis/tendon rupture by the combination of Prednisone and Trovafloxacin.	Bacterial infection [1A00-1C4Z]	[40]
Sparfloxacin	DMB4HCT	Major	Increased risk of tendinitis/tendon rupture by the combination of Prednisone and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[40]
Gemifloxacin	DMHT34O	Major	Increased risk of tendinitis/tendon rupture by the combination of Prednisone and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[40]
Norfloxacin	DMIZ6W2	Major	Increased risk of tendinitis/tendon rupture by the combination of Prednisone and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[40]
ABT-492	DMJFD2I	Major	Increased risk of tendinitis/tendon rupture by the combination of Prednisone and ABT-492.	Bacterial infection [1A00-1C4Z]	[40]
Levofloxacin	DMS60RB	Major	Increased risk of tendinitis/tendon rupture by the combination of Prednisone and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[40]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Prednisone caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[37]
Lomefloxacin	DMVRH9C	Major	Increased risk of tendinitis/tendon rupture by the combination of Prednisone and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[40]
Telithromycin	DMZ4P3A	Moderate	Decreased metabolism of Prednisone caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[37]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Prednisone caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[42]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Prednisone caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[37]
Vilanterol	DMF5EK1	Minor	Increased risk of hypokalemia by the combination of Prednisone and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[38]
Salmeterol	DMIEU69	Minor	Increased risk of hypokalemia by the combination of Prednisone and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[37]
Indacaterol	DMQJHR7	Minor	Increased risk of hypokalemia by the combination of Prednisone and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[37]
Arformoterol	DMYM974	Minor	Increased risk of hypokalemia by the combination of Prednisone and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[37]
Phenylbutazone	DMAYL0T	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Prednisone and Phenylbutazone.	Chronic pain [MG30]	[34]
Ketoprofen	DMRKXPT	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Prednisone and Ketoprofen.	Chronic pain [MG30]	[34]
Isoproterenol	DMK7MEY	Minor	Increased risk of hypokalemia by the combination of Prednisone and Isoproterenol.	Conduction disorder [BC63]	[38]
Mivacurium	DM473VD	Moderate	Additive neuromuscular blocking effects by the combination of Prednisone and Mivacurium.	Corneal disease [9A76-9A78]	[37]
Pancuronium	DMB0VY8	Moderate	Additive neuromuscular blocking effects by the combination of Prednisone and Pancuronium.	Corneal disease [9A76-9A78]	[37]
Tubocurarine	DMBZIVP	Moderate	Additive neuromuscular blocking effects by the combination of Prednisone and Tubocurarine.	Corneal disease [9A76-9A78]	[37]
Mifepristone	DMGZQEF	Major	Decreased metabolism of Prednisone caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[43]
Lumacaftor	DMCLWDJ	Moderate	Increased metabolism of Prednisone caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[44]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Prednisone caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[45]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Prednisone caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[46]
Aprepitant	DM053KT	Moderate	Decreased metabolism of Prednisone caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[47]
Nefazodone	DM4ZS8M	Moderate	Decreased metabolism of Prednisone caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[37]
Primidone	DM0WX6I	Moderate	Increased metabolism of Prednisone caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[48]
Oxcarbazepine	DM5PU6O	Moderate	Increased metabolism of Prednisone caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[49]
Cenobamate	DMGOVHA	Moderate	Increased metabolism of Prednisone caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[50]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Prednisone caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[51]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Prednisone caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[52]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Prednisone caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[39]
Ethotoin	DMXWOCP	Moderate	Increased metabolism of Prednisone caused by Ethotoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[52]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Prednisone caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[48]
Mefenamic acid	DMK7HFI	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Prednisone and Mefenamic acid.	Female pelvic pain [GA34]	[34]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Prednisone caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[53]
Itraconazole	DMCR1MV	Moderate	Decreased metabolism of Prednisone caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[37]
Ketoconazole	DMPZI3Q	Moderate	Decreased metabolism of Prednisone caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[37]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Prednisone caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[37]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Prednisone caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[54]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Prednisone caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[55]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Prednisone caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[56]
Delavirdine	DM3NF5G	Moderate	Decreased metabolism of Prednisone caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[37]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Prednisone caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[37]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Prednisone caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[37]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Prednisone caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[57]
Amprenavir	DMLMXE0	Moderate	Decreased metabolism of Prednisone caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[37]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Prednisone caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[37]
Atazanavir	DMSYRBX	Moderate	Decreased metabolism of Prednisone caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[37]
Bempedoic acid	DM1CI9R	Major	Increased risk of tendinitis/tendon rupture by the combination of Prednisone and Bempedoic acid.	Hyper-lipoproteinaemia [5C80]	[58]
Teriflunomide	DMQ2FKJ	Major	Additive immunosuppressive effects by the combination of Prednisone and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[59]
Conivaptan	DM1V329	Moderate	Decreased metabolism of Prednisone caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[37]
Meclofenamic acid	DM05FXR	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Prednisone and Meclofenamic acid.	Inflammatory spondyloarthritis [FA92]	[60]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Prednisone caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[61]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Prednisone caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[48]
ITI-007	DMUQ1DO	Major	Increased metabolism of Prednisone caused by ITI-007 mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[62]
Denosumab	DMNI0KO	Moderate	Additive immunosuppressive effects by the combination of Prednisone and Denosumab.	Low bone mass disorder [FB83]	[63]
Ceritinib	DMB920Z	Moderate	Decreased metabolism of Prednisone caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[37]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Prednisone caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[64]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Prednisone caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[39]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Prednisone caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[37]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Prednisone caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[65]
Nivolumab	DMAB9QE	Moderate	Additive immunosuppressive effects by the combination of Prednisone and Nivolumab.	Melanoma [2C30]	[37]
Pembrolizumab	DMFQEA6	Moderate	Additive immunosuppressive effects by the combination of Prednisone and Pembrolizumab.	Melanoma [2C30]	[37]
Ipilimumab	DMJTIYK	Moderate	Additive immunosuppressive effects by the combination of Prednisone and Ipilimumab.	Melanoma [2C30]	[37]
Cemiplimab	DMKMJHE	Moderate	Additive immunosuppressive effects by the combination of Prednisone and Cemiplimab.	Melanoma [2C30]	[37]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Prednisone caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[39]
Thalidomide	DM70BU5	Major	Additive thrombogenic effects by the combination of Prednisone and Thalidomide.	Multiple myeloma [2A83]	[66]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Prednisone and Tecfidera.	Multiple sclerosis [8A40]	[67]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Prednisone and Siponimod.	Multiple sclerosis [8A40]	[38]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Prednisone and Fingolimod.	Multiple sclerosis [8A40]	[68]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Prednisone and Ocrelizumab.	Multiple sclerosis [8A40]	[69]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Prednisone and Ozanimod.	Multiple sclerosis [8A40]	[39]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Prednisone caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[37]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Prednisone caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[70]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Prednisone caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[71]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive immunosuppressive effects by the combination of Prednisone and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[72]
Modafinil	DMYILBE	Minor	Increased metabolism of Prednisone caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[73]
Bupropion	DM5PCS7	Major	Increased risk of lowers seizure threshold by the combination of Prednisone and Bupropion.	Nicotine use disorder [6C4A]	[74]
Atezolizumab	DMMF8U0	Moderate	Additive immunosuppressive effects by the combination of Prednisone and Atezolizumab.	Non-small cell lung cancer [2C25]	[37]
Naproxen	DMZ5RGV	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Prednisone and Naproxen.	Osteoarthritis [FA00-FA05]	[34]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Prednisone caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[75]
Aspirin	DM672AH	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Prednisone and Aspirin.	Pain [MG30-MG3Z]	[76]
Etodolac	DM6WJO9	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Prednisone and Etodolac.	Pain [MG30-MG3Z]	[34]
Diflunisal	DM7EN8I	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Prednisone and Diflunisal.	Pain [MG30-MG3Z]	[34]
Ibuprofen	DM8VCBE	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Prednisone and Ibuprofen.	Pain [MG30-MG3Z]	[34]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Prednisone caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[77]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Prednisone caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[78]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Prednisone caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[37]
Ritodrine	DM4V6RL	Minor	Increased risk of hypokalemia by the combination of Prednisone and Ritodrine.	Preterm labour/delivery [JB00]	[37]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Prednisone and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[79]
Gatifloxacin	DMSL679	Major	Increased risk of tendinitis/tendon rupture by the combination of Prednisone and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[40]
Salsalate	DM13P4C	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Prednisone and Salsalate.	Rheumatoid arthritis [FA20]	[33]
Meloxicam	DM2AR7L	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Prednisone and Meloxicam.	Rheumatoid arthritis [FA20]	[34]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Prednisone and Canakinumab.	Rheumatoid arthritis [FA20]	[80]
Oxaprozin	DM9UB0P	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Prednisone and Oxaprozin.	Rheumatoid arthritis [FA20]	[34]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Prednisone and Rilonacept.	Rheumatoid arthritis [FA20]	[80]
Flurbiprofen	DMGN4BY	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Prednisone and Flurbiprofen.	Rheumatoid arthritis [FA20]	[34]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Prednisone and Golimumab.	Rheumatoid arthritis [FA20]	[81]
Leflunomide	DMR8ONJ	Major	Additive immunosuppressive effects by the combination of Prednisone and Leflunomide.	Rheumatoid arthritis [FA20]	[59]
Salicyclic acid	DM2F8XZ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Prednisone and Salicyclic acid.	Seborrhoeic dermatitis [EA81]	[76]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Prednisone when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[82]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Prednisone caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[37]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Prednisone caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[39]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Prednisone caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[38]
Armodafinil	DMGB035	Minor	Increased metabolism of Prednisone caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[73]
LEE011	DMMX75K	Moderate	Decreased metabolism of Prednisone caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[83]
Pitolisant	DM8RFNJ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Prednisone and Pitolisant.	Somnolence [MG42]	[39]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Prednisone caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[84]
Pipecuronium	DM5F84A	Moderate	Additive neuromuscular blocking effects by the combination of Prednisone and Pipecuronium.	Tonus and reflex abnormality [MB47]	[37]
Doxacurium	DMKE7L9	Moderate	Additive neuromuscular blocking effects by the combination of Prednisone and Doxacurium.	Tonus and reflex abnormality [MB47]	[37]
Vecuronium	DMP0UK2	Moderate	Additive neuromuscular blocking effects by the combination of Prednisone and Vecuronium.	Tonus and reflex abnormality [MB47]	[37]
Rocuronium	DMY9BMK	Moderate	Additive neuromuscular blocking effects by the combination of Prednisone and Rocuronium.	Tonus and reflex abnormality [MB47]	[37]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Prednisone and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[79]
Tacrolimus	DMZ7XNQ	Moderate	Increased plasma concentrations of Prednisone and Tacrolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[79]
Durvalumab	DM4PVDY	Moderate	Additive immunosuppressive effects by the combination of Prednisone and Durvalumab.	Ureteral cancer [2C92]	[37]
Cinoxacin	DM4EWNS	Major	Increased risk of tendinitis/tendon rupture by the combination of Prednisone and Cinoxacin.	Urinary tract infection [GC08]	[40]
Nalidixic acid	DMRM0JV	Major	Increased risk of tendinitis/tendon rupture by the combination of Prednisone and Nalidixic acid.	Urinary tract infection [GC08]	[40]
-----------


⏷ Show the Full List of 131 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Docusate sodium	E00563	23673837	Surfactant
Hydrochloric acid	E00015	313	Acidulant
Maltol	E00175	8369	Flavoring agent
Quinoline yellow WS	E00309	24671	Colorant
Saccharin sodium anhydrous	E00443	656582	Flavoring agent
Sodium benzoate	E00432	517055	Antimicrobial preservative; lubricant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite	E00392	104805	Diluent
Carmellose sodium	E00625	Not Available	Disintegrant
Citric acid monohydrate	E00271	22230	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Crospovidone	E00626	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Fructose	E00447	2723872	Flavoring agent
Glyceryl dibehenate	E00537	22477175	Binding agent; Coating agent; Flavoring agent; Modified-release agent; Viscosity-controlling agent; lubricant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Poloxamer 188	E00645	Not Available	Emulsifying agent; Solubilizing agent; Surfactant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Propylene glycol distearate	E00395	110800	Emollient; Opacifying agent; Surfactant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Water	E00035	962	Solvent
--------------------


⏷ Show the Full List of 26 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Prednisone 10 mg tablet	10 mg	Oral Tablet	Oral
Prednisone 1 mg tablet	1 mg	Oral Tablet	Oral
Prednisone 2.5 mg tablet	2.5 mg	Oral Tablet	Oral
Prednisone 5 mg tablet	5 mg	Oral Tablet	Oral
Prednisone 1 mg tablet	1 mg	Delayed Release Oral Tablet	Oral
Prednisone 2 mg tablet	2 mg	Delayed Release Oral Tablet	Oral
Prednisone 5 mg tablet	5 mg	Delayed Release Oral Tablet	Oral
Prednisone 20 mg tablet	20 mg	Oral Tablet	Oral
Prednisone 50 mg tablet	50 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7096).
2	Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	BDDCS applied to over 900 drugs
5	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8	Cytochromes P450 (CYP) in the Poeciliopsis lucida hepatocellular carcinoma cell line (PLHC-1): dose- and time-dependent glucocorticoid potentiation of CYP1A induction without induction of CYP3A. ArchBiochem Biophys. 1996 May 1;329(1):113-22.
9	Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803.
10	Cytochrome P450 enzyme regulation by glucocorticoids and consequences in terms of drug interaction. Expert Opin Drug Metab Toxicol. 2014 Mar;10(3):425-35.
11	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
12	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
13	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
14	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
15	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
16	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
17	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
18	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
19	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
20	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
21	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
22	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
23	Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
24	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
25	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
26	Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
27	Interaction between the glucocorticoid and erythropoietin receptors in human erythroid cells. Exp Hematol. 2009 May;37(5):559-72.
28	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
29	Aldosterone (mineralocorticoid) equivalent to prednisolone (glucocorticoid) in reversing hearing loss in MRL/MpJ-Fas1pr autoimmune mice. Laryngoscope. 2000 Nov;110(11):1902-6.
30	Fluticasone furoate nasal spray in allergic rhinitis. Drugs Today (Barc). 2008 Apr;44(4):251-60.
31	PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide. Eur J Pharm Sci. 2009 Mar 2;36(4-5):565-71.
32	The glucocorticoid agonist activities of mifepristone (RU486) and progesterone are dependent on glucocorticoid receptor levels but not on EC50 values. Steroids. 2007 Jun;72(6-7):600-8.
33	Baer PA, Shore A, Ikeman RL "Transient fall in serum salicylate levels following intraarticular injection of steroid in patients with rheumatoid arthritis." Arthritis Rheum 30 (1987): 345-7. [PMID: 3566826]
34	Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
35	Albin H, Vincon G, Demotes-Mainard F, et al "Effect of aluminium phosphate on the bioavailability of cimetidine and prednisolone." Eur J Clin Pharmacol 26 (1984): 271-3. [PMID: 6723769]
36	Brooks SM, Werk EE, Ackerman SJ, Sullivan I, Thrasher K "Adverse effects of phenobarbital on corticosteroid metabolism in patients with bronchial asthma." N Engl J Med 286 (1972): 1125-8. [PMID: 4553339]
37	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
38	Cerner Multum, Inc. "Australian Product Information.".
39	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
40	FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008].".
41	Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
42	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
43	Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
44	Cerner Multum, Inc. "Canadian Product Information.".
45	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
46	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
47	Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
48	Bartoszek M, Brenner AM, Szefler SJ "Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy." Clin Pharmacol Ther 42 (1987): 424-32. [PMID: 3665340]
49	Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
50	Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
51	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
52	Frey BM, Frey FJ "Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans." Eur J Clin Invest 14 (1984): 1-6. [PMID: 6230241]
53	Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
54	Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
55	Kyriazopoulou V, Parparousi O, Vagenakis AG "Rifampicin-induced adrenal crisis in Addisonian patients receiving corticosteroid replacement therapy." J Clin Endocrinol Metab 59 (1984): 1204-6. [PMID: 6490796]
56	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
57	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
58	Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
59	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
60	Messer J, Reitman D, Sacks HS, et al "Association of adrenocorticosteroid therapy and peptic-ulcer disease." N Engl J Med 309 (1983): 21-4. [PMID: 6343871]
61	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
62	Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
63	Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
64	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
65	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
66	Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
67	Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
68	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
69	Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
70	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
71	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
72	Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
73	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
74	Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
75	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
76	Hansen RA, Tu W, Wang J, Ambuehl R, McDonald CJ, Murray MD "Risk of adverse gastrointestinal events from inhaled corticosteroids." Pharmacotherapy 28 (2008): 1325-34. [PMID: 18956992]
77	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
78	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
79	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
80	Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
81	Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
82	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
83	DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
84	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.